赵瑜，助理教授、研究员、博士生导师。2006年7月获得青岛大学医学院生物技术专业学士学位，2012年7月获得南开大学生命科学学院生物化学与分子生物学专业博士学位。作为第一完成人，获全国颠覆性技术创新大赛优秀奖1项，中国健康长寿创新大赛三等奖1项。获得美国生物医学Kendall C. Edward奖学金1项，辽宁省科技进步一等奖。获得天津市杰出青年科学基金、天津市重点项目等资助。 院校引进人才，2021年加入院校，曾在2012年7月进入梅奥医院攻读博士后，并于2017年7月任梅奥医院研究助理，2018年5月至2021年2月任梅奥医院助理教授。

长期从事新型核药和核药新靶点研究，提出核药靶点研发不同于传统药物的“司机-乘客蛋白互换”新理论和核药-免疫联合治疗新策略；创立核药高效入核新技术，节省核素、降低核药使用成本2倍以上，解决核药诊疗贵的难题。承担天津市杰青项目等5项国家和省部级科研课题，在Nature Medicine等杂志发表论文50余篇，H指数29，2篇被引次数破200，4篇被引破100，3篇被国际专利引用，进入临床研究。主编国际专著章节2部，参编1部。培养博士、硕士、博士后10余名，研究生获国家奖学金2人。

     1. Shao C#, Zhang Y#, Li H#, Chen J#, Huang T, Li J, Wen S, Wang S, Fan S, Zhao Y*. Radiotherapy-resistant prostate cancer cells escape immune checkpoint blockade through the senescence-related ataxia telangiectasia and Rad3-related protein. Cancer Commun (Lond). 2024 Dec 19. doi: 10.1002/cac2.12636.

2. Wen S#, Wei Y#, Zen C, Xiong W, Niu Y, Zhao Y*. Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine. Molecular Cancer. 2020 Dec 12;19(1):171. (C100)

3. Zhang P.#, Wang D.#, Zhao Y.#, Ren S.#, Gao K.#, Ye Z., Wang S., Pan C.W., Zhu Y., Yan Y., Yang Y., Wu D., He Y., Zhang J., Lu D., Liu X., Yu L., Zhao S., Li Y., Lin D., Wang Y., Wang L., Chen Y., Sun Y.*, Wang C.*, Huang H.*, Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation, Nature Medicine, 23 (2017) 1055-1062. (C100)

4. Zhao Y#, Ding L#, Wang D, Ye Z, He Y, Ma L, Zhu R, Pan Y, Wu Q, Pang K, Hou X, Weroha SJ, Han C, Coleman R, Coleman I, Karnes RJ, Zhang J, Nelson PS, Wang L#, Huang H#. EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. EMBO J. 2019 Mar 1;38(5):e99599. (C100)

5. Zhao Y, Wang L, Ren S, Wang L, Blackburn PR, McNulty MS, Gao X, Qiao M, Vessella RL, Kohli M, Zhang J, Karnes RJ, Tindall DJ, Kim Y, MacLeod R, Ekker SC, Kang T, Sun Y#, Huang H*. Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer. Cell Rep. 2016 Apr 19;15(3):599-610. (C100)

6. Huang Y, Li J, Wang S, Tian H*, Fan S*, Zhao Y*. Diselenide-based nanoparticles enhancing the radioprotection to the small intestine of mice. J Nanobiotechnology. 2025 Mar 22;23(1):236. doi: 10.1186/s12951-025-03276-3.

7. Yue T, Dong Y, Huo Q, Li W, Wang X, Zhang S, Fan H, Wu X, He X, Zhao Y*, Li D*. Nicotinamide riboside alleviates ionizing radiation-induced intestinal senescence by alleviating oxidative damage and regulating intestinal metabolism. J Adv Res. 2025 Jun;72:421-432.

8. Li W, Wang X, Dong Y, Huo Q, Yue T, Wu X, Lu L, Zhang J, Zhao Y*, Dong H*, Li D*. Nicotinamide riboside intervention alleviates hematopoietic system injury of ionizing radiation-induced premature aging mice. Aging Cell. 2023 Nov;22(11):e13976.

9. Li H#, Zhao S, Jiang M, Zhu T, Liu J, Feng G, Lu L, Dong J, Wu X, Chen X, Zhao Y*, Fan S*. Biomodified Extracellular Vesicles Remodel the Intestinal Microenvironment to Overcome Radiation Enteritis. ACS Nano. 2023 Jul 25;17(14):14079-14098.

10. Dai D#, Yu J#, Huang T#, Li Y, Wang Z, Yang S, Li S, Li Y, Gou W, Li D, Hou W, Fan S*, Li Y*, Zhao Y*. PET imaging of new target CDK19 in prostate cancer. Eur J Nucl Med Mol Imaging. 2023 Jun 6.